GB201914747D0 - PD1 and vegfr2 dual-binding agents - Google Patents

PD1 and vegfr2 dual-binding agents

Info

Publication number
GB201914747D0
GB201914747D0 GB201914747A GB201914747A GB201914747D0 GB 201914747 D0 GB201914747 D0 GB 201914747D0 GB 201914747 A GB201914747 A GB 201914747A GB 201914747 A GB201914747 A GB 201914747A GB 201914747 D0 GB201914747 D0 GB 201914747D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
vegfr2
dual
vegfr2 dual
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201914747A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultrahuman Eight Ltd
Original Assignee
Ultrahuman Eight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrahuman Eight Ltd filed Critical Ultrahuman Eight Ltd
Priority to GB201914747A priority Critical patent/GB201914747D0/en
Publication of GB201914747D0 publication Critical patent/GB201914747D0/en
Priority to GBGB2013180.1A priority patent/GB202013180D0/en
Priority to AU2020365021A priority patent/AU2020365021A1/en
Priority to CN202080075802.2A priority patent/CN114981301A/en
Priority to JP2022521074A priority patent/JP2022553908A/en
Priority to US17/768,013 priority patent/US20240101674A1/en
Priority to CA3156096A priority patent/CA3156096A1/en
Priority to PCT/EP2020/078427 priority patent/WO2021069670A1/en
Priority to EP20789105.2A priority patent/EP4041763A1/en
Priority to KR1020227014433A priority patent/KR20220091490A/en
Priority to IL292158A priority patent/IL292158A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
GB201914747A 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents Ceased GB201914747D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents
KR1020227014433A KR20220091490A (en) 2019-10-11 2020-10-09 PD1 and VEGFR2 double binding agent
JP2022521074A JP2022553908A (en) 2019-10-11 2020-10-09 PD1 and VEGFR2 double binding agents
CN202080075802.2A CN114981301A (en) 2019-10-11 2020-10-09 PD1 and VEGFR2 dual binding agents
AU2020365021A AU2020365021A1 (en) 2019-10-11 2020-10-09 PD1 and VEGFR2 dual-binding agents
US17/768,013 US20240101674A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
CA3156096A CA3156096A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
PCT/EP2020/078427 WO2021069670A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
EP20789105.2A EP4041763A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents
IL292158A IL292158A (en) 2019-10-11 2022-04-11 Pd1 and vegfr2 dual-binding agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents

Publications (1)

Publication Number Publication Date
GB201914747D0 true GB201914747D0 (en) 2019-11-27

Family

ID=68619556

Family Applications (2)

Application Number Title Priority Date Filing Date
GB201914747A Ceased GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GBGB2013180.1A Ceased GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2013180.1A Ceased GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents

Country Status (10)

Country Link
US (1) US20240101674A1 (en)
EP (1) EP4041763A1 (en)
JP (1) JP2022553908A (en)
KR (1) KR20220091490A (en)
CN (1) CN114981301A (en)
AU (1) AU2020365021A1 (en)
CA (1) CA3156096A1 (en)
GB (2) GB201914747D0 (en)
IL (1) IL292158A (en)
WO (1) WO2021069670A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143935A (en) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 Recombinant antibodies and uses thereof
WO2024032662A1 (en) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 Antibody targeting pd-1 and vegf, and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742379T3 (en) * 2012-05-31 2020-02-14 Hoffmann La Roche Cancer treatment procedures using PD-1 axis binding antagonists and VEGF antagonists
RS59480B1 (en) * 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Also Published As

Publication number Publication date
IL292158A (en) 2022-06-01
WO2021069670A1 (en) 2021-04-15
CN114981301A (en) 2022-08-30
GB202013180D0 (en) 2020-10-07
EP4041763A1 (en) 2022-08-17
KR20220091490A (en) 2022-06-30
US20240101674A1 (en) 2024-03-28
AU2020365021A1 (en) 2022-05-26
CA3156096A1 (en) 2021-04-15
JP2022553908A (en) 2022-12-27

Similar Documents

Publication Publication Date Title
IL271025A (en) Multibiotic agents and methods of using the same
ZA202002172B (en) Pde9 inhibitor and use thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
SG11202008246VA (en) Pd1 binding agents
PL3543240T3 (en) Urat1 inhibitor and use thereof
IL282350A (en) Rgmc-selective inhibitors and use thereof
SG11202004877UA (en) Sulfonamide compounds and use thereof
IL292158A (en) Pd1 and vegfr2 dual-binding agents
GB2591554B (en) Composiitons and methods and uses relating thereto
EP3585814A4 (en) Egfr-binding agents and uses thereof
IL277131A (en) Pd1 binding agents
IL282527A (en) Azaindazole-5 derivatives and their use
EP4063489A4 (en) Composition and use thereof
IL292692A (en) Mrgprx2 antagonists and uses thereof
PT3796975T (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
IL282526A (en) Azaindazole-5 derivatives and their use
IL277749A (en) Pladienolide compounds and their use
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
IL289531A (en) Cd38-binding agents and uses thereof
IL288828A (en) Cd38-binding agents and uses thereof
IL280369A (en) New myokines and uses thereof
EP4028502A4 (en) N-acyl-tyrosine derivatives and uses thereof
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
IL269843B (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
GB2589437B (en) Circuitry and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)